Lowest Price Guaranteed
Pages
150
Last Updated
April 2026
View Count
27903
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Alzheimer’s Disease
3.1.1. Alzheimer’s Disease: Signs and Symptoms
3.1.2. Causes of Alzheimer’s Disease
3.1.3. Stages of Alzheimer’s Disease
3.2. Alzheimer’s Disease Management: Programs Undertaken by The National Institutes of Health
3.3. Alzheimer’s Disease Management
3.4. Digital Biomarkers in Alzheimer’s Disease
3.4.1. Potential of Digital Biomarkers in Alzheimer’s Disease
3.4.2. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer’s Disease
4. PIPELINE REVIEW: MARKETED AND CLINICAL- STAGE DRUGS
4.1. Analysis Methodology and Key Parameters
4.2. Alzheimer’s Disease Therapies: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Target Disease Stage
4.2.4. Analysis by Type of Treatment
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosing Frequency
4.2.8. Analysis by Type of Therapy
4.2.9. Analysis by Path to Clinic
4.2.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
4.4. Alzheimer’s Disease Therapies: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location of Headquarters
4.4.3. Leading Players: Analysis by Number of Therapies
4.4.4. Analysis by Geography
5. COMPANY PROFILES
5.1. AbbVie
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. AC Immune
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Biogen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Eisai
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Eli Lilly and Company
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. GlaxoSmithKline
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Grifols
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Janssen Pharmaceutical
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. Neurim Pharmaceuticals
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook
5.10. Novartis
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Product Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. Novo Nordisk
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Product Portfolio
5.11.4. Recent Developments and Future Outlook
5.12. Roche
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Product Portfolio
5.12.4. Recent Developments and Future Outlook
5.13. Takeda Pharmaceutical
5.13.1. Company Overview
5.13.2. Financial Information
5.13.3. Product Portfolio
5.13.4. Recent Developments and Future Outlook
6. CASE STUDY: TERMINATED DRUGS
6.1. Chapter Overview
6.2. Alzheimer’s Disease Therapies: List of Terminated Drugs
6.2.1. Analysis by Year of Discontinuation
6.2.2. Analysis by Phase of Discontinuation
6.2.3. Analysis by Mechanism of Action
6.2.4. Analysis by Type of Indication
6.2.5. Analysis by Reason for Termination
6.2.6. Analysis by Affiliated Stakeholders
6.3. Alzheimer’s Disease Therapies: List of Terminated Clinical Trials
6.3.1. Distribution by Study Start Year and Year of Termination of Clinical Trials
6.3.2. Analysis by Location of Trials
6.4. Concluding Remarks
7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Alzheimer’s Disease: List of Publications
7.3. Analysis by Year of Publication
7.4. Analysis by Key Focus Area
7.5. Word Cloud of Study Titles
7.6. Top Journal: Analysis by Number of Publications
7.6. Top Author: Analysis by Number of Publications
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Analysis Methodology and Key Parameters
8.2. Partnership Models
8.3. Alzheimer’s Disease: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partnership and Focus Area of Partnership
8.3.4. Analysis by Type of Partnership and Type of Molecule
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.3.6. Regional Analysis
8.3.7. Intercontinental and Intracontinental Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Types of Funding
9.3. Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4 Analysis by Amount Invested Across Different Types of Molecules
9.3.5 Analysis by Amount Invested Across Different Types of Mechanism of Action
9.3.6. Regional Analysis by Amount Invested
9.3.7. Most Active Players: Analysis by Number of Funding Instances
9.3.8. Most Active Investors: Analysis by Amount Funded
10. GRANT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Alzheimer’s Disease: List of Academic Grants
10.2.1. Analysis by Year of Grant Award
10.2.2. Analysis by Grant Amount Awarded
10.2.3. Analysis by Administering Institute Center
10.2.4. Analysis by Support Period
10.2.5. Analysis by Administering Institute Center and Support Year
10.2.6. Analysis by Type of Grant Application
10.2.7. Analysis by Grant Activity Code
10.2.8. Word Cloud of Study Titles
10.2.9. Analysis by Purpose of Grant Award
10.2.10. Analysis by Type of Recipient Organization
10.2.11. Popular NIH Departments: Analysis by Number of Grants
10.2.12. Prominent Program Officers: Analysis by Number of Grants
11. CLINICAL TRIAL ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Alzheimer’s Disease: Clinical Trial Analysis
11.3.1. Analysis by Trial Status
11.3.2. Analysis by Trial Registration Year
11.3.3. Analysis by Type of Sponsor / Collaborator
11.3.3. Analysis by Type of Study Design
11.3.4. Analysis by Registration Year and Type of Study
11.3.5. Analysis by Patient Enrollment
11.3.6. Year-wise Trend of Completed and Recruiting Trials
11.3.7. Analysis by Age Category
11.3.8. Word Cloud of Study Titles
11.3.9. Most Active Industry Players: Analysis by Number of Registered Trials
11.3.10. Most Active Non- Industry Players: Analysis by Number of Registered Trials
11.3.11. Analysis by Trial Location
11.3.12. Analysis by Trial Status and Geography
12. PATENT ANALYSIS
12.1. Analysis Methodology and Key Parameters
12.2. Alzheimer’s Disease: Patent Analysis
12.2.1. Analysis by Patent Application Year
12.2.2. Analysis by Geography
12.2.3. Analysis by CPC Symbols
12.2.4. Word Cloud: Emerging Focus Areas
12.2.5. Analysis by Type of Applicant
12.2.6. Leading Players: Analysis by Number of Patents
12.2.7 Leading Players: Analysis by Number of International Patents
12.2.8. Patent Valuation Analysis
13. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS
13.1. Non-Pharmacological Interventions for Alzheimer’s Disease
13.1.1. Cognition / Emotion-Oriented Interventions
13.1.1.1. Reminiscence Therapy
13.1.1.2. Simulated Presence Therapy
13.1.2. Sensory Stimulation-based Interventions
13.1.2.1. Virtual Reality
13.1.2.2. Music Therapy
13.1.2.3. Light Therapy
13.1.2.4. Aromatherapy
13.1.2.5. Reflexology
13.1.3. Other Psycho-social Interventions
13.1.3.1. Animal-Assisted Therapy
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Forecast Methodology and Key Assumptions
14.2. Global Alzheimer’s Disease Market, 2021-2035
14.3. Global Alzheimer’s Disease Market, 2021-2035: Distribution by Type of Treatment
14.4. Global Alzheimer’s Disease Market, 2021-2035: Distribution by Type of Target Disease Indication
14.5. Global Alzheimer’s Disease Market, 2021-2035: Distribution by Geography
14.5.1. Alzheimer’s Disease Market in North America, 2021-2035
14.5.1.1. Alzheimer’s Disease Market in North America, 2021-2035: Distribution by Type of Treatment
14.5.1.1.1. Alzheimer’s Disease Market in North America, 2021-2035: Distribution by Symptomatic Treatment
14.5.1.1.1.1. Alzheimer’s Disease Market in North America, 2021-2035: Share of Dementia in Symptomatic Treatment Market
14.5.1.1.1.2. Alzheimer’s Disease Market in North America, 2021-2035: Share of Insomnia in Symptomatic Treatment Market
14.5.1.1.1.3. Alzheimer’s Disease Market in North America, 2021-2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
14.5.1.1.2. Alzheimer’s Disease Market in North America, 2021-2035: Distribution by Disease Modifying Treatment
14.5.2. Alzheimer’s Disease Market in Europe, 2021-2035
14.5.2.1. Alzheimer’s Disease Market in Europe, 2021-2035: Distribution by Type of Treatment
14.5.2.1.1. Alzheimer’s Disease Market in Europe, 2021-2035: Distribution by Symptomatic Treatment
14.5.2.1.1.1. Alzheimer’s Disease Market in Europe, 2021-2035: Share of Dementia in Symptomatic Treatment Market
14.5.2.1.1.2. Alzheimer’s Disease Market in Europe, 2021-2035: Share of Insomnia in Symptomatic Treatment Market
14.5.2.1.1.3. Alzheimer’s Disease Market in Europe, 2021-2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
14.5.2.1.2. Alzheimer’s Disease Market in Europe, 2021-2035: Distribution by Disease Modifying Treatment
14.5.3. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035
14.5.3.1. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Distribution by Type of Treatment
14.5.3.1.1. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Distribution by Symptomatic Treatment
14.5.3.1.1.1. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Share of Dementia in Symptomatic Treatment Market
14.5.3.1.1.2. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Share of Insomnia in Symptomatic Treatment Market
14.5.3.1.1.3. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
14.5.3.1.2. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Distribution by Disease Modifying Treatment
15. CONCLUDING REMARKS
16. EXECUTIVE INSIGHTS
16.1. Cognition Therapeutics
16.1.1. Company Snapshot
16.1.1. Interview Transcript: Kenneth Moch (President and Chief Executive Officer)
16.2. ArmaGen
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Mathias Schmidt (Chief Executive Officer)
16.2. ICB International
16.2.1. Company Snapshot
16.3.2. Interview Transcript: Ram Bhatt (Chief Executive Officer, Chairman and Founder)
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1. Overview of Alzheimer’s Disease
Figure 3.2. Alzheimer’s Disease: Signs and Symptoms
Figure 3.3. Causes of Alzheimer’s Disease
Figure 3.4. Stages of Alzheimer’s Disease
Figure 3.5. Alzheimer’s Disease Management: Programs Undertaken by The National Institutes of Health
Figure 3.6. Alzheimer’s Disease Management
Figure 3.7. Digital Biomarkers in Alzheimer’s Disease
Figure 3.8. Potential of Digital Biomarkers in Alzheimer’s Disease
Figure 3.9. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer’s Disease
Figure 4.1. Marketed and Clinical-Stage Drugs: Distribution by Phase of Development
Figure 4.2. Marketed and Clinical-Stage Drugs: Distribution by Type of Molecule
Figure 4.3. Marketed and Clinical-Stage Drugs: Distribution by Target Disease Stage
Figure 4.4. Marketed and Clinical-Stage Drugs: Distribution by Type of Treatment
Figure 4.5. Marketed and Clinical-Stage Drugs: Distribution by Mechanism of Action
Figure 4.6. Marketed and Clinical-Stage Drugs: Distribution by Route of Administration
Figure 4.7. Marketed and Clinical-Stage Drugs: Distribution by Dosing Frequency
Figure 4.8. Marketed and Clinical-Stage Drugs: Distribution by Type of Therapy
Figure 4.9. Marketed and Clinical-Stage Drugs: Distribution by Path to Clinic
Figure 4.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
Figure 4.11. Alzheimer’s Disease Therapies: List of Developers
Figure 4.12. Alzheimer’s Disease Therapy Developers: Distribution by Year of Establishment
Figure 4.13. Alzheimer’s Disease Therapy Developers: Distribution by Company Size and Geographical Location of Headquarters
Figure 4.14. Leading Players: Distribution by Number of Therapies
Figure 4.15. Alzheimer’s Disease Therapy Developers: Distribution by Geography
Figure 5.1. AbbVie: Financial Information
Figure 5.2. AC Immune: Financial Information
Figure 5.3. Biogen: Financial Information
Figure 5.4. Eisai: Financial Information
Figure 5.5. Eli Lilly and Company: Financial Information
Figure 5.6. GlaxoSmithKline: Financial Information
Figure 5.7. Grifols: Financial Information
Figure 5.8. Janssen Pharmaceutical: Financial Information
Figure 5.9. Neurim Pharmaceuticals: Financial Information
Figure 5.10. Novartis: Financial Information
Figure 5.11. Novo Nordisk: Financial Information
Figure 5.12. Roche: Financial Information
Figure 5.13. Takeda Pharmaceutical: Financial Information
Figure 6.1. Terminated Drugs: Distribution by Year of Discontinuation
Figure 6.2. Terminated Drugs: Distribution by Phase of Discontinuation
Figure 6.3. Terminated Drugs: Distribution by Mechanism of Action
Figure 6.4. Terminated Drugs: Distribution by Type of Indication
Figure 6.5. Terminated Drugs: Distribution by Reason for Termination
Figure 6.6. Terminated Drugs: Distribution by Affiliated Stakeholders
Figure 6.7. Terminated Drugs: Distribution by Study Start Year and Year of Termination of Clinical Trials
Figure 6.8. Terminated Drugs: Distribution by Location of Trials
Figure 7.1. Publication Analysis: Distribution by Year of Publication
Figure 7.2. Publication Analysis: Distribution by Key Focus Area
Figure 7.3. Publication Analysis: Word Cloud of Study Titles
Figure 7.4. Top Journals: Distribution by Number of Publications
Figure 7.5. Top Authors: Distribution by Number of Publications
Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area of Partnership
Figure 8.4. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Molecule
Figure 8.5. Most Active Players: Distribution by Number of Partnerships
Figure 8.6. Partnerships and Collaborations: Regional Distribution
Figure 8.7. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1. Funding and Investment Analysis: Distribution by Year of Investment
Figure 9.2. Funding and Investment Analysis: Distribution by Amount Invested
Figure 9.3. Funding and Investment Analysis: Distribution by Type of Funding
Figure 9.4. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Molecules
Figure 9.5. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Mechanism of Action
Figure 9.6. Funding and Investment Analysis: Regional Distribution by Amount Invested
Figure 9.7. Most Active Players: Distribution by Number of Funding Instances
Figure 9.8. Most Active Investors: Distribution by Amount Funded
Figure 10.1. Grant Analysis: Distribution by Year of Grant Award
Figure 10.2. Grant Analysis: Distribution by Grant Amount Awarded
Figure 10.3. Grant Analysis: Distribution by Administering Institute Center
Figure 10.4. Grant Analysis: Distribution by Support Period
Figure 10.5. Grant Analysis: Distribution by Administering Institute Center and Support Year
Figure 10.6. Grant Analysis: Distribution by Type of Grant Application
Figure 10.7. Grant Analysis: Distribution by Grant Activity Code
Figure 10.8. Grant Analysis: Word Cloud of Study Titles
Figure 10.9. Grant Analysis: Distribution by Purpose of Grant Award
Figure 10.10. Grant Analysis: Distribution by Type of Recipient Organization
Figure 10.11. Popular NIH Departments: Distribution by Number of Grants
Figure 10.12. Prominent Program Officers: Distribution by Number of Grants
Figure 11.1. Clinical Trial Analysis: Distribution by Trial Status
Figure 11.2. Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 11.3. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.4. Clinical Trial Analysis: Distribution by Type of Study Design
Figure 11.5. Clinical Trial Analysis: Distribution by Registration Year and Type of Study
Figure 11.6. Clinical Trial Analysis: Distribution by Patient Enrollment
Figure 11.7. Clinical Trial Analysis: Year-wise Trend of Completed and Recruiting Trials
Figure 11.8. Clinical Trial Analysis: Distribution by Age Category
Figure 11.9. Clinical Trial Analysis: Word Cloud of Study Titles
Figure 11.10. Most Active Industry Players: Distribution by Number of Registered Trials
Figure 11.11. Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.12. Clinical Trial Analysis: Distribution by Trial Location
Figure 11.13. Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 12.1. Patent Analysis: Distribution by Patent Application Year
Figure 12.2. Patent Analysis: Distribution by Geography
Figure 12.3. Patent Analysis: Distribution by CPC Symbols
Figure 12.4. Word Cloud: Emerging Focus Areas
Figure 12.5. Patent Analysis: Distribution by Type of Applicant
Figure 12.6. Leading Players: Distribution by Number of Patents
Figure 12.7 Leading Players: Distribution by Number of International Patents
Figure 12.8. Patent Analysis: Patent Valuation Analysis
Figure 13.1. Non-Pharmacological Interventions for Alzheimer’s Disease
Figure 13.2. Cognition / Emotion-Oriented Interventions
Figure 13.3. Reminiscence Therapy
Figure 13.4. Simulated Presence Therapy
Figure 13.5. Sensory Stimulation-based Interventions
Figure 13.6. Virtual Reality
Figure 13.7. Music Therapy
Figure 13.8. Light Therapy
Figure 13.9. Aromatherapy
Figure 13.10. Reflexology
Figure 13.11. Other Psycho-social Interventions
Figure 13.12. Animal-Assisted Therapy
Figure 14.1. Global Alzheimer’s Disease Market, 2021-2035 (USD Million)
Figure 14.2. Global Alzheimer’s Disease Market, 2021-2035: Distribution by Type of Treatment (USD Million)
Figure 14.3. Global Alzheimer’s Disease Market, 2021-2035: Distribution by Type of Target Disease Indication (USD Million)
Figure 14.4. Global Alzheimer’s Disease Market, 2021-2035: Distribution by Geography (USD Million)
Figure 14.5. Alzheimer’s Disease Market in North America, 2021-2035 (USD Million)
Figure 14.6. Alzheimer’s Disease Market in North America, 2021-2035: Distribution by Type of Treatment (USD Million)
Figure 14.7. Alzheimer’s Disease Market in North America, 2021-2035: Distribution by Symptomatic Treatment (USD Million)
Figure 14.8. Alzheimer’s Disease Market in North America, 2021-2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
Figure 14.9. Alzheimer’s Disease Market in North America, 2021-2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
Figure 14.10. Alzheimer’s Disease Market in North America, 2021-2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
Figure 14.11. Alzheimer’s Disease Market in North America, 2021-2035: Distribution by Disease Modifying Treatment (USD Million)
Figure 14.12. Alzheimer’s Disease Market in Europe, 2021-2035 (USD Million)
Figure 14.13. Alzheimer’s Disease Market in Europe, 2021-2035: Distribution by Type of Treatment (USD Million)
Figure 14.14. Alzheimer’s Disease Market in Europe, 2021-2035: Distribution by Symptomatic Treatment (USD Million)
Figure 14.15. Alzheimer’s Disease Market in Europe, 2021-2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
Figure 14.16. Alzheimer’s Disease Market in Europe, 2021-2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
Figure 14.17. Alzheimer’s Disease Market in Europe, 2021-2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
Figure 14.18. Alzheimer’s Disease Market in Europe, 2021-2035: Distribution by Disease Modifying Treatment (USD Million)
Figure 14.19. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035(USD Million)
Figure 14.20. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Distribution by Type of Treatment (USD Million)
Figure 14.21. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Distribution by Symptomatic Treatment (USD Million)
Figure 14.22. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Share of Dementia in Symptomatic Treatment (USD Million)
Figure 14.23. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Share of Insomnia in Symptomatic Treatment (USD Million)
Figure 14.24. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Share of Other Psychological Symptoms in Symptomatic Treatment (USD Million)
Figure 14.25. Alzheimer’s Disease Market in Asia-Pacific, 2021-2035: Distribution by Disease Modifying Treatment (USD Million)
Table 4.1 Alzheimer’s Disease: Marketed and Clinical Development Pipeline
Table 4.2 Alzheimer’s Disease Therapies: List of Developers
Table 6.1 Alzheimer’s Disease Therapies: List of Terminated Drugs
Table 7.1 Alzheimer’s Disease: List of Publications
Table 8.1 Alzheimer’s Disease: List of Partnerships and Collaborations
Table 9.1 Alzheimer’s Disease: List of Funding and Investments
Table 10.1 Alzheimer’s Disease: List of Academic Grants
Table 11.1 Alzheimer’s Disease: List of Clinical Trials
Table 12.1 Alzheimer’s Disease: List of Patents
The following companies and organizations have been mentioned in the report.
Source 1: www.who.int/news-room/fact-sheets/detail/dementia#:~:text=Alzheimer's%20disease%20is%20the%20most,60%E2%80%9370%25%20of%20cases
Source 2: www.biopharmadive.com/news/alzheimers-drugs-amyloid-biogen-aduhelm-approval/601483/